gebhart/patrepeval huggingface dataset:
Photonic components for future fiber access networks (2010)

Fiber based access networks are recognized as promising technologies for solving broadband bandwidth bottlenecks. TDM-PONs, which are passive and non-reconfigurable, are the most widely deployed type of fiber access networks today. However, due to their passive nature, TDM-PONs encounter several issues such as inflexible coverage, lack of intelligence for control, and inability to counter security attacks. Based on current issues in optical access networks, we propose a novel non-volatile, reconfiguration node. The proposed remote node can reconfigure the network to adapt to varying degrees of deployment conditions and/or network attacks. Moreover, the proposed remote node incorporates a novel quasi-passive device that reconfigures using remotely supplied energy from CO. This quasi-passive device technology does not consume any energy once it reconfigures into a new latching states. Therefore, the proposed remote node has very low energy consumption and does not require local power supply to preserve the passivity of the passive distribution network. In particular, the proposed quasi-passive device technology is implemented using a novel tri-state Micro- Electro-Mechanical System (MEMS) actuator structure and the device demonstrates very small energy consumption requirement to enable energy be remotely supplied from CO. Also, the MEMS structure is shown to demonstrate acceptable insertion losses to makes it suitable for flexible energy distribution. Simulation study shows the proposed reconfigurable device would outperform traditional passive splitter in terms of maximum number of supportable users under realistic deployment conditions.
Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation (2015)

Treatment of relapsed chronic lymphocytic leukemia (CLL) with ibrutinib results in high rates of progression-free and overall survival. Ibrutinib, an irreversible Bruton's tyrosine kinase inhibitor, may also modulate donor T cell alloimmunity via interleukin-2-inducible kinase inhibition. We report results of ibrutinib salvage therapy in 5 high risk CLL patients who relapsed following allogeneic hematopoietic cell transplantation (allo-HCT). Lymph node (LN) size was measured by CT scan, CLL minimal residual disease (MRD) levels by IgH high-throughput sequencing (HTS) (ClonoSIGHTTM test, Sequenta Inc.), donor CD3 chimerism by short tandem repeat analysis, and donor B cell immune reconstitution by IgH HTS quantification of total IgH molecules and unique IgH clonotypes. All 4 patients with pathologic lymphadenopathy prior to treatment experienced dramatic LN reduction on ibrutinib (Fig 1A; 68% average reduction after 3 mos). Patients SPN3975 (17p del) and SPN3431 (11q del) achieved undetectable CLL MRD (<10-6) after 39 mos and 8 mos, respectively (Fig 1B, 1C). SPN3975 had failed to maintain full donor CD3 chimerism after dose-escalated donor lymphocyte infusions but after 1 yr of ibrutinib achieved full donor chimerism. Oral and skin chronic graft-versus-host disease (cGVHD) additionally resolved after 6 mos. Two additional patients have increased donor chimerism since starting ibrutinib. Although SPN3975 has not taken ibrutinib for >10 mos, full donor chimerism persists and CLL MRD remains undetectable (Fig 1B). Prior to ibrutinib, donor B cells in this patient (excluding the CLL clone) accounted for <0.2% of total PBMC. Following discontinuation of ibrutinib, donor B cells increased within 6 mos and now comprise >1% of PBMC (Fig 1D). Furthermore, recovering B cells have diverse, low frequency IgH clonotypes (Fig 1E). Ibrutinib provides effective salvage therapy for CLL relapse following allo-HCT and demonstrates promising donor immune modulation, promoting full donor chimerism and cGVHD resolution. Here we present 2 post allo-HCT CLL relapse patients who achieved MRD negativity on ibrutinib, one of whom maintains undetectable CLL 10 mos after stopping therapy. Our findings show rapid, sustained, and diverse immune reconstitution without CLL recurrence following discontinuation. Clinical trials are needed to determine the duration of therapy for post allo-HCT relapse, role of ibrutinib maintenance, and cGVHD treatment efficacy.
Silica as a Ligand: Reactivity of the Iridium-Oxygen Bond of Cp*Ir[silica](Ph)(PMe3) (1994)

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTSilica as a Ligand: Reactivity of the Iridium-Oxygen Bond of Cp*Ir[silica](Ph)(PMe3)Tara Y. Meyer, K. A. Woerpel, Bruce M. Novak, and Robert G. BergmanCite this: J. Am. Chem. Soc. 1994, 116, 22, 10290–10291Publication Date (Print):November 1, 1994Publication History Published online1 May 2002Published inissue 1 November 1994https://pubs.acs.org/doi/10.1021/ja00101a055https://doi.org/10.1021/ja00101a055research-articleACS PublicationsRequest reuse permissionsArticle Views320Altmetric-Citations45LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-AlertscloseSupporting Info (2)»Supporting Information Supporting Information Get e-Alerts
Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans (1995)

In the present studies we investigated the effect of interferon-alpha (IFN alpha) on the release of the soluble (extracellular) form of the tumor necrosis factor p55 receptor (TNFsRp55), because TNFsRp55 is a natural antagonist of tumor necrosis factor (TNF)-induced inflammation and also might be part of the antiinflammatory properties of IFN alpha. Plasma levels of TNFsRp55 were measured by a specific radioimmunoassay in five healthy volunteers and in five patients with chronic hepatitis C treated with IFN alpha. Levels showed a significant increase after a single injection of 5.0 million U IFN alpha in both healthy and hepatitis patient groups. Peak values (3.5 to 4.5 ng/mL) were observed within 12 hours of beginning treatment. Thereafter, levels promptly declined, reaching baseline values within 24 hours. TNF alpha and C- reactive protein (CRP) levels were below the detection limit in the same plasma samples. In addition, IFN alpha suppressed significantly interleukin (IL)-1 alpha-induced TNF alpha protein synthesis by human peripheral blood mononuclear cells. These results suggest that the antiinflammatory properties of IFN alpha may be, in part, also due to the induction and/or release of TNF soluble receptors and the suppression of TNF alpha synthesis.
Evaluation of bonding performance and multi-ion release of S-PRG fillercontaining self-adhesive resin composite (2021)

The bonding performance of a surface pre-reacted glass ionomer (S-PRG) filler-containing self-adhesive flowable resin composites to enamel and dentin were evaluated using a tensile bond test with thermal cycling. Also, the quantities of various ions released from the materials were measured using ICP atomic emission spectrometry and a fluoride ion electrode. The initial bond strengths of the materials were approximately 6 MPa, and decreased after thermal cycling. The S-PRG filler-containing self-adhesive flowable resin composites materials exhibited much higher ion release compared with the commercial self-adhesive flowable resin composite possibly due to different acidic monomers contained. It was suggested that the S-PRG filler containing self-adhesive flowable resin composites should be limited as a lining material or to restore small cavities in non-stress bearing areas.
Single‐Photon Emission: Bright Room‐Temperature Single‐Photon Emission from Defects in Gallium Nitride (Adv. Mater. 12/2017) (2017)

The cover depicts an image of bright single photons emitted from gallium nitride. This illustrates a potential quantum nanoelectronic circuit that uses single photons for information transfer, as described in article number 1605092 by Dirk Englund and Igor Aharonovich.
Package Universes: Which Components Are Real Candidates? (2006)

Package universes is a component-distribution architecture based on explicitly managing the set of components visible at assembly time. The architecture is usable as is for a number of common organizations and software-engineering processes. Also, by providing a context of use for components, it allows several simplifications in the underlying component system. Experience is reported about two prototype implementations and user groups. 1
Rate-distance tradeoff and resource costs for all-optical quantum repeaters (2017)

A detailed analysis of the performance and required resources for an all-photonic quantum repeater architecture is presented. It is shown how to significantly outperform the bit rate achievable by any repeaterless direct-transmission protocol despite various device losses, and also dramatically decrease the number of required photon sources.
Surface antigenic determinants of mammalian "hepadnaviruses" defined by group- and class-specific monoclonal antibodies (1982)

The hepatitis B-like viruses (human hepatitis B virus, woodchuck hepatitis virus, ground squirrel hepatitis virus, and duck hepatitis B virus) are hepatotropic DNA viruses which have been referred to collectively as "hepadnaviruses." Using a murine monoclonal antibody (101-2) to the surface antigen of woodchuck hepatitis virus, we have shown that the surface antigens of mammalian hepadnaviruses (HBsAg, WHsAg, and GSHsAg) are antigenically related via a common determinant (HV/101). Furthermore, analysis with other monoclonal antibodies to WHsAg revealed that WHsAg and GHsAg are antigenically distinct, although the antigens had more determinants in common with each other than with HBsAg. The hepadnavirus group-specific antibody (101-2) reacted with HBsAg subtypic variants in a group-specific rather than subtype-specific manner. In conjunction with observations with an HBsAg-specific, group-reactive monoclonal antibody (BX259), the present data suggest that there are at least two group-reactive epitopes of HBsAg: one which is virus specific (HBV/259) and one which is common to two other mammalian hepadnaviruses (HV/101).
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance (2022)

Estrogen receptor alpha (ERα) drives mammary gland development and breast cancer (BC) growth through an evolutionarily conserved linkage of DNA binding and hormone activation functions. Therapeutic targeting of the hormone binding pocket is a widely utilized and successful strategy for breast cancer prevention and treatment. However, resistance to this endocrine therapy is frequently encountered and may occur through bypass or reactivation of ER-regulated transcriptional programs. We now identify the induction of an ERα isoform, ERα-LBD, that is encoded by an alternative ESR1 transcript and lacks the activation function and DNA binding domains. Despite lacking the transcriptional activity, ERα-LBD is found to promote breast cancer growth and resistance to the ERα antagonist fulvestrant. ERα-LBD is predominantly localized to the cytoplasm and mitochondria of BC cells and leads to enhanced glycolysis, respiration and stem-like features. Intriguingly, ERα-LBD expression and function does not appear to be restricted to cancers that express full length ERα but also promotes growth of triple-negative breast cancers and ERα-LBD transcript (ESR1-LBD) is also present in BC samples from both ERα(+) and ERα(-) human tumors. These findings point to ERα-LBD as a potential mediator of breast cancer progression and therapy resistance.
Flexible Microneedle Array Patch for Chronic Wound Oxygenation and Biofilm Eradication (2021)

Chronic nonhealing wounds are a growing socioeconomic problem that affects more than 6 million people annually solely in the United States. These wounds are colonized by bacteria that often develop into biofilms that act as a physical and chemical barrier to therapeutics and tissue oxygenation leading to chronic inflammation and tissue hypoxia. Although wound debridement and vigorous mechanical abrasion techniques are often used by clinical professionals to manage and remove biofilms from wound surfaces, such methods are highly nonselective and painful. In this study, we have developed a flexible polymer composite microneedle array that can overcome the physicochemical barriers (i.e., bacterial biofilm) present in chronic nonhealing wounds and codeliver oxygen and bactericidal agents. The polymeric microneedles are made by using a facile UV polymerization process of polyvinylpyrrolidone and calcium peroxide onto a flexible polyethylene terephthalate substrate for conformable attachment onto different locations of the human body surface. The microneedles effectively elevate the oxygen levels from 8 to 12 ppm once dissolved over the course of 2 h while also providing strong bactericidal effects on both liquid and biofilm bacteria cultures of both Gram-positive (<i>Staphylococcus aureus</i>) and Gram-negative (<i>Pseudomonas aeruginosa</i>) bacterial strains commonly found in dermal wounds. Furthermore, the results from the ex vivo assay on a porcine wound model indicated successful insertion of the microneedles into the tissue while also providing effective bactericidal properties against both Gram-positive and Gram-negative within the complex tissue matrix. Additionally, the microneedles demonstrate high levels of cytocompatibility with less than 10% of apoptosis throughout 6 days of continuous exposure to human dermal fibroblast cells. The demonstrated flexible microneedle array can provide a better approach for increasing the effectiveness of topical tissue oxygenation as well as the treatment of infected wounds with intrinsically antibiotic resistant biofilms.
Impact of Adalimumab therapy after 12 Weeks in patients with Crohnʼs Disease who were nonresponders at week 4 (2008)

Adalimumab, a fully human antibody targeting tumor necrosis factor, is approved for treatment of adults with moderate to severe Crohn's disease (CD). In clinical trials, 52-58% of patients responded to adalimumab by Week 41,2; however, some patients require additional time to respond. Additional data on the length of an adequate trial of adalimumab may benefit physicians when making treatment decisions. This analysis assessed the efficacy of adalimumab by Week 12 among patients who did not respond after 4 weeks using data from 2 clinical trials: the Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance (CHARM) and the open-label extension (OLE) of the Gauging Adalimumab Efficacy in Infliximab Nonresponders (GAIN) study. In CHARM, following a 4-week induction period in which all patients received OL adalimumab 80 mg/40 mg at Weeks 0/2, patients were randomized to placebo, adalimumab 40 mg every other week (eow), or adalimumab 40 mg weekly. In GAIN, patients who failed infliximab were randomized to adalimumab 160 mg/80 mg or placebo induction at Weeks 0/2. After 4 weeks, patients could enroll in an OLE study in which they received adalimumab 40 mg eow. Remission (CD Activity Index [CDAI] <150) and clinical response (CR-70; defined as a decrease from baseline CDAI of greater than or equal to 70 points) rates by Week 12 were evaluated for CHARM patients who were randomized to blinded adalimumab 40 mg eow and did not achieve a CR-70 response at Week 4 and GAIN patients who received OL adalimumab 40 mg eow after being randomized to the blinded adalimumab 160-/80-mg induction dose and did not achieve a CR-70 response at Week 4. In CHARM, 260 patients were initially randomized to blinded adalimumab 40 mg eow. Among 88 patients who did not respond (CR-70) at Week 4, 60% achieved CR-70 and 28% achieved remission by Week 12. By Week 12, 82% and 57% of patients who were randomized to eow therapy (including Week-4 responders and nonresponders) achieved CR-70 and remission, respectively. In GAIN, 159 patients were initially randomized to adalimumab 160 mg/80 mg; 150 with nonmissing CDAI entered the OLE. Among 69 patients who did not respond (CR-70) at Week 4, 67% receiving OL adalimumab 40 mg eow achieved CR-70 and 25% achieved remission by Week 12. Combining responders and nonresponders (n = 150), most patients achieved CR-70 response (85%) and remission (45%) by Week 12. Most initial Week-4 nonresponders benefited from continued treatment with adalimumab 40 mg eow through Week 12, with almost two-thirds achieving CR-70 response and more than one-fourth achieving remission. When continuing adalimumab therapy for up to 12 weeks, incremental benefits in clinical response were demonstrated in patients not responding to initial induction dosing.
ChemInform Abstract: Syntheses and Diels‐Alder Cycloaddition Reactions of 4H‐Furo(3,4‐b) indoles. A Regiospecific Diels‐Alder Synthesis of Ellipticine. (1993)

Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Direct observation of above-quantum-step quasibound states inGaAs/AlxGa1−xAs/vacuumheterostructures (1998)

In this paper we demonstrate the existence of above-quantum-step quasibound states in ${\mathrm{G}\mathrm{a}\mathrm{A}\mathrm{s}/\mathrm{A}\mathrm{l}}_{0.24}{\mathrm{Ga}}_{0.76}\mathrm{A}\mathrm{s}/\mathrm{v}\mathrm{a}\mathrm{c}\mathrm{u}\mathrm{u}\mathrm{m}$ double heterostructures using a modulated photoreflection spectroscopy technique at room temperature. A series of clearly resolved structures was found in the spectra. Their energy positions agree well with those of transitions between quasibound states in the state density of the heteorostructure. Further envelope wave-function analysis indicates that these quasibound states mainly center in the ${\mathrm{G}\mathrm{a}\mathrm{A}\mathrm{s}/\mathrm{A}\mathrm{l}}_{0.24}{\mathrm{Ga}}_{0.76}\mathrm{As}$ quantum-step region, and are found to be affected by the limited length of electron coherence.
Supplementary Figure 2 from T Cell Receptor Genotyping and <i>HOXA/TLX1</i> Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome (2023)

Supplementary Figure 2 from T Cell Receptor Genotyping and &lt;i&gt;HOXA/TLX1&lt;/i&gt; Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome
Investigation of polarization-pinning mechanism in deep-line-etched vertical-cavity surface-emitting lasers (2000)

Recently, it has been shown that the etching of deep trenches in close proximity to GaAs vertical-cavity surface-emitting laser (VCSEL) apertures causes the linearly polarized TE emission to be pinned in a direction parallel to the line etch. In this letter, we show that etching introduces compressive strain or relaxes tensile strain through the creation of free interfaces. An anisotropic variation of strain is the origin of the polarization pinning effect. We report on the enhancement of polarization pinning by postannealing after etching. Photoluminescence and Raman measurements of the VCSEL wafer were taken before and after etching and annealing. The observed shift in the Fabry–Perot mode was used to model the strain, giving 4×108 dyn/cm2, or 0.05%, compressive strain perpendicular to the etch.
Use of Field Based Loop Mediated Isothermal Amplification (LAMP) Technology for a Prevalence Survey and Proof of Freedom Survey for African Swine Fever in Timor-Leste in 2019 (2021)

African Swine Fever (ASF) has been spreading in numerous southeast Asian countries since a major incursion in mainland China in 2018. Timor-Leste confirmed an outbreak of ASF in September 2019 which resulted in high mortalities in affected pigs. Pigs in Timor-Leste are the second most common type of livestock kept by villagers and represent a traditionally important source of income and prestige for householders. In order to understand the extent of ASF infected villages in Timor-Leste a prevalence survey was designed and conducted in November-December 2019. Timor-Leste has limited laboratory facilities and access to qPCR diagnostic tests. Therefore, a loop mediated isothermal amplification (LAMP) assay was used to detect ASF positive blood samples collected during the prevalence survey. The LAMP assay was proven to be a robust, highly specific and sensitive laboratory test for ASF suitable for use in the field and where there are limited laboratory facilities. The results of the prevalence survey allowed the extent of the ASF incursion to be delineated and the introduction of a disease response strategy to limit the spread of ASF and assist in the recovery of the pig population in Timor-Leste.
Open Label Extension of the Phase 3 Study NEURO-TTR to Assess the Long-term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis (P1.324) (2018)

To report long-term efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of transthyretin protein production, in the Phase 3 open-label extension (OLE) study (NCT02175004).
Inkjet 3D Printing of Polymers Resistant to Fungal Attachment (2021)

Inkjet 3D printing is an additive manufacturing method that allows the user to produce a small batch of customized devices for comparative study versus commercial products. Here, we describe the use of a commercial 2D ink development system (Dimatix material printing) to manufacture small batches of 3D medical or other devices using a recently characterized fungal anti-attachment material. Such printed devices may resist problems that beset commercial medical products due to colonization by the fungal pathogen <i>Candida albicans</i>. By sequentially introducing the cross-section bitmaps of the product's CAD model and elevating the print head height using the auto-clicking script, we were able to create complex self-support geometries with the 2D ink development system. The use of this protocol allows researchers to produce a small batch of specimens for characterization from only a few grams of raw material. Additionally, we describe the testing of manufactured specimens for fungal anti-attachment. In comparison with most commercial AM systems, which require at least a few hundred grams of ink for printing trials, our protocol is well suited for smaller-scale production in material studies.
A 1–12‐GHz variable‐gain low‐noise amplifier MMIC using 0.25‐μm SiGe BiCMOS technology (2012)

Abstract This article introduces an 1–12‐GHz differential two‐stage variable‐gain low‐noise amplifier (VGLNA) using 0.25‐μm SiGe:C BiCMOS commercial process technology for ultra‐wideband system.The results of the fabricated monolithic microwave integrated circuit amplifier show 18‐dB gain with a 3‐dB frequency band of 1.3–11.9 GHz and noise figure of less than 5 dB under the bias condition of 2.5‐V supply voltage and 55‐mW total dc power consumption. The gain‐control range is from −17 dB to +18 dB. The chip size of the manufactured VGLNA is 1.1 × 0.9 mm 2 including all testing pads for RF and dc probes. © 2012 Wiley Periodicals, Inc. Microwave Opt Technol Lett 54:1935–1937, 2012; View this article online at wileyonlinelibrary.com. DOI 10.1002/mop.26936